ID

33722

Beschrijving

Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus; ODM derived from: https://clinicaltrials.gov/show/NCT01326026

Link

https://clinicaltrials.gov/show/NCT01326026

Trefwoorden

Versies (1)
  1. 20-12-18 20-12-18 -
Houder van rechten

See clinicaltrials.gov

Geüploaded op

20 december 2018

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY 4.0
Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Terug naar het model Commentaren
Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Diabetes NCT01326026

Engels

Eligibility Diabetes NCT01326026

1 Formulieren  
  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT01326026
Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
type 2 diabetes (diagnosed clinically) for at least 24 weeks prior to randomisation (visit 2)
Beschrijving

Diabetes Mellitus, Non-Insulin-Dependent

Datatype

boolean

Alias
UMLS CUI [1]
C0011860
current treatment: metformin monotherapy or metformin in any combination with 1 or 2 other oads including an insulin secretagogue (sulfonylurea or glinide), dipeptidyl peptidase iv (dpp-iv) inhibitors, alpha-glucosidase inhibitors, thiazolidinediones (tzds) all with unchanged dosing for at least 12 weeks prior to randomisation (visit 2)-metformin: alone or in combination (including fixed combination) must be at least 1000 mg daily
Beschrijving

Metformin | Combined Modality Therapy | Antidiabetics Oral Quantity | Pills Insulin Release | Sulfonylurea | Glinide | DPP-4 Inhibitor | alpha-Glucosidase Inhibitors | Thiazolidinediones | Pharmaceutical Preparations Dose unchanged

Datatype

boolean

Alias
UMLS CUI [1]
C0025598
UMLS CUI [2]
C0009429
UMLS CUI [3,1]
C0935929
UMLS CUI [3,2]
C1527415
UMLS CUI [3,3]
C1265611
UMLS CUI [4,1]
C0994475
UMLS CUI [4,2]
C0021641
UMLS CUI [4,3]
C1283071
UMLS CUI [5]
C0038766
UMLS CUI [6]
C2266929
UMLS CUI [7]
C3537225
UMLS CUI [8]
C1299007
UMLS CUI [9]
C1257987
UMLS CUI [10,1]
C0013227
UMLS CUI [10,2]
C0178602
UMLS CUI [10,3]
C0442739
hba1c 7.0-10.0% (both inclusive) by central laboratory analysis
Beschrijving

Hemoglobin A1c measurement

Datatype

boolean

Alias
UMLS CUI [1]
C0474680
bmi (body mass index) no higher than 45.0 kg/m^2
Beschrijving

Body mass index

Datatype

boolean

Alias
UMLS CUI [1]
C1305855
Exclusion Criteria
Beschrijving

Exclusion Criteria

Alias
UMLS CUI
C0680251
treatment with glucagon-like peptide 1 (glp-1) receptor agonist within the last 12 weeks prior to visit 2
Beschrijving

GLP-1 Receptor Agonist

Datatype

boolean

Alias
UMLS CUI [1]
C2917359
suffer from a life threatening disease (e.g. cancer)
Beschrijving

Life threatening illness | Malignant Neoplasms

Datatype

boolean

Alias
UMLS CUI [1]
C3846017
UMLS CUI [2]
C0006826
females of childbearing potential who are pregnant (as determined by central laboratory beta-human chorionic gonadotropin (beta-hcg), breast feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptive methods as required by law or practise [for germany, adequate contraceptive methods are: implants, injectables, combined oral contraceptives, hormonal iud, sexual abstinence or vasectomised partner])
Beschrijving

Pregnancy Serum pregnancy test (B-HCG) | Breast Feeding | Pregnancy, Planned | Childbearing Potential Contraceptive methods Absent | Contraceptive implant | Injectable contraception | Combined Oral Contraceptives | Intrauterine Devices, Medicated | Sexual Abstinence | Partner had vasectomy

Datatype

boolean

Alias
UMLS CUI [1,1]
C0032961
UMLS CUI [1,2]
C0430060
UMLS CUI [2]
C0006147
UMLS CUI [3]
C0032992
UMLS CUI [4,1]
C3831118
UMLS CUI [4,2]
C0700589
UMLS CUI [4,3]
C0332197
UMLS CUI [5]
C1657106
UMLS CUI [6]
C1262153
UMLS CUI [7]
C0009906
UMLS CUI [8]
C0021902
UMLS CUI [9]
C0036899
UMLS CUI [10]
C0420842
Terug naar het begin van de pagina

Similar models

Eligibility Diabetes NCT01326026

1 Formulieren
  1. StudyEvent: Eligibility
    1. Eligibility Diabetes NCT01326026
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
Diabetes Mellitus, Non-Insulin-Dependent
Item
type 2 diabetes (diagnosed clinically) for at least 24 weeks prior to randomisation (visit 2)
boolean
C0011860 (UMLS CUI [1])
Metformin | Combined Modality Therapy | Antidiabetics Oral Quantity | Pills Insulin Release | Sulfonylurea | Glinide | DPP-4 Inhibitor | alpha-Glucosidase Inhibitors | Thiazolidinediones | Pharmaceutical Preparations Dose unchanged
Item
current treatment: metformin monotherapy or metformin in any combination with 1 or 2 other oads including an insulin secretagogue (sulfonylurea or glinide), dipeptidyl peptidase iv (dpp-iv) inhibitors, alpha-glucosidase inhibitors, thiazolidinediones (tzds) all with unchanged dosing for at least 12 weeks prior to randomisation (visit 2)-metformin: alone or in combination (including fixed combination) must be at least 1000 mg daily
boolean
C0025598 (UMLS CUI [1])
C0009429 (UMLS CUI [2])
C0935929 (UMLS CUI [3,1])
C1527415 (UMLS CUI [3,2])
C1265611 (UMLS CUI [3,3])
C0994475 (UMLS CUI [4,1])
C0021641 (UMLS CUI [4,2])
C1283071 (UMLS CUI [4,3])
C0038766 (UMLS CUI [5])
C2266929 (UMLS CUI [6])
C3537225 (UMLS CUI [7])
C1299007 (UMLS CUI [8])
C1257987 (UMLS CUI [9])
C0013227 (UMLS CUI [10,1])
C0178602 (UMLS CUI [10,2])
C0442739 (UMLS CUI [10,3])
Hemoglobin A1c measurement
Item
hba1c 7.0-10.0% (both inclusive) by central laboratory analysis
boolean
C0474680 (UMLS CUI [1])
Body mass index
Item
bmi (body mass index) no higher than 45.0 kg/m^2
boolean
C1305855 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
GLP-1 Receptor Agonist
Item
treatment with glucagon-like peptide 1 (glp-1) receptor agonist within the last 12 weeks prior to visit 2
boolean
C2917359 (UMLS CUI [1])
Life threatening illness | Malignant Neoplasms
Item
suffer from a life threatening disease (e.g. cancer)
boolean
C3846017 (UMLS CUI [1])
C0006826 (UMLS CUI [2])
Pregnancy Serum pregnancy test (B-HCG) | Breast Feeding | Pregnancy, Planned | Childbearing Potential Contraceptive methods Absent | Contraceptive implant | Injectable contraception | Combined Oral Contraceptives | Intrauterine Devices, Medicated | Sexual Abstinence | Partner had vasectomy
Item
females of childbearing potential who are pregnant (as determined by central laboratory beta-human chorionic gonadotropin (beta-hcg), breast feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptive methods as required by law or practise [for germany, adequate contraceptive methods are: implants, injectables, combined oral contraceptives, hormonal iud, sexual abstinence or vasectomised partner])
boolean
C0032961 (UMLS CUI [1,1])
C0430060 (UMLS CUI [1,2])
C0006147 (UMLS CUI [2])
C0032992 (UMLS CUI [3])
C3831118 (UMLS CUI [4,1])
C0700589 (UMLS CUI [4,2])
C0332197 (UMLS CUI [4,3])
C1657106 (UMLS CUI [5])
C1262153 (UMLS CUI [6])
C0009906 (UMLS CUI [7])
C0021902 (UMLS CUI [8])
C0036899 (UMLS CUI [9])
C0420842 (UMLS CUI [10])
Terug naar het begin van de pagina 

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial